Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۰۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–0
- Intermediate Risk1–2
- High Risk3–27
The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) calculates predicting survival after HCT in patients with hematologic malignancies, including optional age adjustment. Key inputs include arrhythmia. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.
Clinical Indication
The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is indicated for bedside clinical practice to support Predicts survival after HCT in patients with hematologic malignancies, including optional age adjustment. The HCT-CI comprises 17 different categories of organ dysfunction and has been validated as more sensitive than the Charlson Comorbidity Index for HCT patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
Sum of points assigned to each comorbidity: Arrhythmia (1), Cardiac CAD/CHF/MI/EF≤50% (1), Cardiac valve disease (3), IBD (1), Diabetes treated (1), Cerebrovascular (1), Psychiatric (1), Mild hepatic (1), Moderate/severe hepatic (3), Obesity BMI>35 (1), Infection (1), Rheumatologic (2), Peptic ulcer (2), Moderate/severe renal (2), Moderate pulmonary (2), Severe pulmonary (3), Prior solid tumor (3). Age adjustment adds 1 point if age ≥40 years.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| arrhythmia | string | Yes | History of arrhythmia |
| cardiac | string | Yes | Cardiac dysfunction |
| inflammatory_bowel | string | Yes | Inflammatory bowel disease |
| diabetes | string | Yes | Diabetes |
| cerebrovascular | string | Yes | Cerebrovascular disease |
| psychiatric | string | Yes | Psychiatric disturbance |
| hepatic | string | Yes | Hepatic dysfunction |
| obesity | string | Yes | Obesity (BMI > 35 kg/m²) |
| infection | string | Yes | Infection requiring antimicrobial treatment after day 0 |
| rheumatologic | string | Yes | Rheumatologic disease |
| peptic_ulcer | string | Yes | Peptic ulcer disease |
| renal | string | Yes | Renal dysfunction |
| pulmonary | string | Yes | Pulmonary dysfunction |
| prior_solid_tumor | string | Yes | Prior solid tumor (treated at any time, excluding non-melanoma skin cancer) |
| include_age | string | Yes | Include age adjustment (Sorror 2014) |
| age | integer | No | Patient age in years (required if age adjustment is included)(years) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Low Risk | Score 0 |
| 1–2 | Intermediate Risk | Score 1-2 |
| 3–27 | High Risk | Score ≥3 |
Evidence-Based References (EBM)
- Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912-9.
- Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014 Oct 10;32(29):3249-56.
- Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood. 2014 Jul 10;124(2):287-95.